tiprankstipranks
Advertisement
Advertisement

NAMS Stock Latest News

NewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement
Company AnnouncementsNewAmsterdam Pharma Announces Chief Accounting Officer Transition Agreement
3d ago
8K
NAMS
NewAmsterdam Pharma: Undervalued Growth Story With Upcoming Clinical Catalysts Supporting Buy Rating
PremiumRatings
NewAmsterdam Pharma: Undervalued Growth Story With Upcoming Clinical Catalysts Supporting Buy Rating
13d ago
NAMS
NewAmsterdam Pharma initiated with a Buy at Truist
PremiumThe Fly
NewAmsterdam Pharma initiated with a Buy at Truist
1M ago
NAMS
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation
PremiumCompany Announcements
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation
2M ago
8K
NAMS
Reaffirming Buy on NewAmsterdam Pharma: Optimized Expense Outlook and Milestone Upside Strengthen Risk‑Reward Profile
PremiumRatings
Reaffirming Buy on NewAmsterdam Pharma: Optimized Expense Outlook and Milestone Upside Strengthen Risk‑Reward Profile
2M ago
NAMS
NewAmsterdam Pharma management to meet virtually with Piper Sandler
PremiumThe FlyNewAmsterdam Pharma management to meet virtually with Piper Sandler
2M ago
NAMS
NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim
Premium
The Fly
NewAmsterdam Pharma price target raised to $45 from $41 at Guggenheim
2M ago
NAMS
NewAmsterdam Pharma (NAMS): Buy Rating on Strong PREVAIL Momentum, Broad Phase 3 Cardiovascular Program, and Solid Cash Runway
Premium
Ratings
NewAmsterdam Pharma (NAMS): Buy Rating on Strong PREVAIL Momentum, Broad Phase 3 Cardiovascular Program, and Solid Cash Runway
2M ago
NAMS
NewAmsterdam Pharma reports FY25 revenue $22.5M, consensus $23.27M
PremiumThe Fly
NewAmsterdam Pharma reports FY25 revenue $22.5M, consensus $23.27M
2M ago
NAMS
NewAmsterdam Pharma announces upcoming milestones
PremiumThe Fly
NewAmsterdam Pharma announces upcoming milestones
2M ago
NAMS
NewAmsterdam Pharma management to meet with Piper Sandler
PremiumThe Fly
NewAmsterdam Pharma management to meet with Piper Sandler
3M ago
NAMS
NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital
PremiumThe Fly
NewAmsterdam Pharma price target raised to $47 from $44 at RBC Capital
3M ago
NAMS
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
PremiumMarket News3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
3M ago
CYTK
MNPR
NewAmsterdam Pharma: PREVAIL Parallels, Robust Trial Execution, and 2026 Milestones Support Buy Rating
Premium
Ratings
NewAmsterdam Pharma: PREVAIL Parallels, Robust Trial Execution, and 2026 Milestones Support Buy Rating
3M ago
NAMS
NewAmsterdam Pharma: Obicetrapib Momentum, 2026 Inflection Catalysts, and Undervalued Blockbuster Potential Support Buy Rating
Premium
Ratings
NewAmsterdam Pharma: Obicetrapib Momentum, 2026 Inflection Catalysts, and Undervalued Blockbuster Potential Support Buy Rating
4M ago
NAMS
NewAmsterdam Pharma: Late-Stage Obicetrapib Momentum, Regulatory Catalysts, and Strong Cash Position Underpin Buy Rating
PremiumRatings
NewAmsterdam Pharma: Late-Stage Obicetrapib Momentum, Regulatory Catalysts, and Strong Cash Position Underpin Buy Rating
4M ago
NAMS
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress
PremiumCompany Announcements
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress
4M ago
8K
NAMS
NewAmsterdam Pharma highlights 2025 achievements, 2026 priorities
PremiumThe Fly
NewAmsterdam Pharma highlights 2025 achievements, 2026 priorities
4M ago
NAMS
NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs
PremiumThe Fly
NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs
5M ago
NAMS
Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential
PremiumRatingsPromising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential
6M ago
NAMS
Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive Advantages
Premium
Ratings
Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive Advantages
6M ago
NAMS
NewAmsterdam Pharma Reports Q3 2025 Financial Results
Premium
Company Announcements
NewAmsterdam Pharma Reports Q3 2025 Financial Results
6M ago
NAMS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >